Name | BRD7389 |
Description | BRD7389 is an inhibitor of RSK family kinase with IC50s of 1.5 μM, 2.4 μM, and 1.2 μM for RSK1, RSK2, and RSK3, respectively. |
In vitro | BRD7389 (1 μM) almost completely blocked Carbachol (1 mM)-stimulated cell proliferation, but has little effect on the basal level of proliferation[1]. BRD7389 (0.425, 0.85, 1.7, 3.4, 6.8 μM) induces insulin expression in mouse α-cells and induces a dose-dependent up-regulation of insulin (Ins2) mRNA, peaking at 0.85 μM. BRD7389 increases β-cell-specific gene expression in primary human islet cells. BRD7389 (0.85-6.8μM) significantly up-regulates Pdx1 mRNA expression in mouse α-cell line[2]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 20 mg/mL (54.58 mM), Sonication and heating to 60℃ are recommended.
|
Keywords | cancer | S6K | Inhibitor | colon | BRD 7389 | inhibit | RSK | islets | diabetes | pancreatic | SNU-407 | BRD-7389 | BRD7389 | Ribosomal S6 Kinase (RSK) |
Inhibitors Related | Ribociclib | Gilteritinib | Nintedanib | Sorafenib | Pexidartinib | Sorafenib tosylate | CASIN | Palbociclib | Sodium Oxamate | Abemaciclib | Sodium salicylate | Dinaciclib |
Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Antidepressant Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Neuronal Differentiation Compound Library |